MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Exposure to bifenthrin contributes to Parkinson’s disease in mouse model

C. Han, S. Liu, J. Huang, L. Liu, K. Ma, X. Guo, S. Guo, L. Wang, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang (Wuhan, China)

Meeting: 2017 International Congress

Abstract Number: 590

Keywords: Alpha-synuclein, Environmental toxins, Parkinsonism

Session Information

Date: Tuesday, June 6, 2017

Session Title: Parkinson's Disease: Pathophysiology

Session Time: 1:45pm-3:15pm

Location: Exhibit Hall C

Objective: To explore the relationship between pyrethroid bifenthrin and Parkinson’s disease on mouse model.

Background: Pyrethroid is now widely used on account of its high efficiency and low toxicity compared to other pesticides. Bifenthrin, one pyrethroid used extensively, was previously demonstrated to cause developmental toxicity. Considering that some pyrethroid was demonstrated to induce dopaminergic degeneration, while the evidence for bifenthrin is still limited.

Methods: Mice were randomly divided into five groups (n=9, per group): vehicle group, 5 mg/kg bifenthrin group, 10 mg/kg bifenthrin group, 20 mg/kg bifenthrin group and 40 mg/kg bifenthrin group. Behavior assessment including pole test and rotarod test were conducted. Detection of dopamine, dopac, homovanilic acid and 5-HT by high performance liquid choromatography were performed. Besides, measurement of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH) were also done. Pathologically, protein level of tyrosine hydroxylase (TH), α-synuclein and vasicular monoamine transporter 2 (VMAT2) were evaluated by western blotting and immunofluorescence or immunohistochemistry.

Results: In this study, we first demonstrated that high dose of bifenthrin was able to cause decreased body weight in mice and bradykinesia indicated by pole test and rotarod test. Pathologically, bifenthrin caused loss of TH and accumulation of α-synuclein. Furthermore, bifenthrin induced decreased expression of VMAT2. Additionally, bifenthrin caused increased oxidative index such as SOD and glutathione which might contribute to the pathological changes.

Conclusions: Our data showed that bifenthrin could induce pathological change resembling PD in mice, providing strong evidence that bifenthrin exposure could contribute to the pathogenesis of PD.

To cite this abstract in AMA style:

C. Han, S. Liu, J. Huang, L. Liu, K. Ma, X. Guo, S. Guo, L. Wang, Y. Shen, Y. Xia, F. Wan, N. Xiong, T. Wang. Exposure to bifenthrin contributes to Parkinson’s disease in mouse model [abstract]. Mov Disord. 2017; 32 (suppl 2). https://www.mdsabstracts.org/abstract/exposure-to-bifenthrin-contributes-to-parkinsons-disease-in-mouse-model/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/exposure-to-bifenthrin-contributes-to-parkinsons-disease-in-mouse-model/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley